Hypotensive effect and subjective symptoms after substitution of 1% dorzolamide by 1% brinzolamide

Japanese Journal of Clinical Ophthalmology

Volumn 58, Issue 2, 2004, Pages 205-209

  Kobayashi, Hiroshi ^a   Kobayashi, Kaori ^a   Okinami, Satoshi ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRINZOLAMIDE; DORZOLAMIDE; LATANOPROST; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUPPING DISK RATIO; DRUG SUBSTITUTION; FEMALE; GLAUCOMA; HUMAN; HUMPHREY PERIMETRY; HYPOTENSIVE EFFECT; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; OPTIC DISK; OPTIC DISK CUP; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERIMETRY; SYMPTOMATOLOGY; VISUAL ACUITY;

EID: 1342323968     PISSN: 03705579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Silver LH: Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. The Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 126: 400-408, 1998
2. Ingram CJ, Brubaker RF: Effect of brimzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol 128: 292-296, 1999
3. March WF, Ochsner KI: The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol 129: 136-143, 2000
4. Seong GJ, Lee SC, Lee JH et al: Comparisons of intraocular-pressure-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. Ophthalmologica 215: 188-191, 2001
5. Michaud JE, Friren B; International Brinzolamide Adjunctive Study Group: Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132: 235-243, 2001
6. Shin D: Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 44 (Suppl 2): 163-168, 2000
7. Barnebey H, Kwok SY: Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 22: 1204-1212, 2000
8. Silver LH: Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. The Brinzolamide Comfort Study Group. Surv Ophthalmol 44 (Suppl 2): 141-145, 2000
9. Glaucoma Q & A. Frontiers in Glaucoma 2: 100-101, 2001
10. Rouland JF, Le Pen C, Gouveia Pinto C et al: Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Pharmacoeconomics 21: 201-213, 2003
11. Vold SD, Riggs WL, Jackimiec J: Cost analysis of glaucoma medications: a 3-year review. J Glaucoma 11: 354-358, 2002